Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,630.96 -315.97 (-0.81%) Hang Seng
19,278.58 +57.96 (+0.30%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,799.34 -1,199.20 (-1.69%) CMC Crypto 200
1,470.42 -18.12 (-1.22%)
GILD Jul 2024 65.000 put
| Previous close | 1.1200 |
| Open | 0.9600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 65.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.9600 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksHere is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
BenzingaGilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim results from the ongoing ASSURE study. The ASSURE study is an open-label study to evaluate the long-term safety and tolerability of seladelpar in people with primary biliary cholangitis (PBC) who have already participated in other PBC clinical trials of seladelpar. The study is currently enrolling up to 500 people. Also Read: Gilead’s Aggressive Push Beyond HIV Treatments
Business WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
FOSTER CITY, Calif., May 18, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC). There are cu
